Singapore, Aug. 19 -- Avixgen, a subsidiary of South Korea-based Dx&Vx, has signed a licensing-out agreement worth approximately $360 million with a US biotechnology company for its next-generation drug delivery platform, ACP (Advanced Cell Penetrating Peptide). Avixgen is a drug development company in which Dx&Vx holds a 66.2% stake.
Through the licensing-out agreement, Avixgen grants the partner company, a US biotechnology company, a limited exclusive license of ACP patents, and the partner applies and develops them only for its own drug development candidates.
The partner will pay Avixgen a total of $360 million in upfront and development milestone payments. Royalties for 10 years after commercialisation are separate. Other specific ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.